Progyny is projected to report Q3 2026 revenue of $340.76 million (+8.7% YoY) and EPS of $0.31, with shares trading near $29.19 against a $34.42 average analyst price target. Investors are primarily focused on fertility benefit utilization rates, which management recently identified as a headwind leading to a full-year 2026 guidance reduction.
Supporting context: The company is working to demonstrate that a recent slowdown in member engagement is a temporary seasonal effect rather than a structural demand shift. Analysts will also scrutinize progress on the 2027 selling season and new client wins to validate Progyny's long-term growth story following a period of elevated attrition and major client losses earlier in the cycle.